Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 2Active not recruiting 2Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Other hematologic neoplasm 2Breast 2Lymphoid 1

Conditions

Breast Neoplasms 1131Triple Negative Breast Neoplasms 147Neoplasm Metastasis 99Carcinoma, Non-Small-Cell Lung 85Ovarian Neoplasms 81Neoplasms 75Lung Neoplasms 64Colorectal Neoplasms 60Melanoma 59Stomach Neoplasms 44Pancreatic Neoplasms 43Breast Neoplasms, Male 43Prostatic Neoplasms 42Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 34Sarcoma 30Colonic Neoplasms 29Endometrial Neoplasms 28Head and Neck Neoplasms 26Brain Neoplasms 24Urinary Bladder Neoplasms 22Esophageal Neoplasms 21Carcinoma, Ovarian Epithelial 21Carcinoma, Intraductal, Noninfiltrating 21Lymphoma, Non-Hodgkin 19Recurrence 18Uterine Cervical Neoplasms 17Inflammatory Breast Neoplasms 17Breast Carcinoma In Situ 17Multiple Myeloma 16

Interventions

tucatinib 1Trastuzumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Meningeal Neoplasms × Breast × Clear all
NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

NCT05414123 2023-10-16

FORESEE

Biocept, Inc.

Terminated
40 enrolled
BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡